Caris Life Sciences, Inc. (CAI) Stock Price & How to Invest

Caris Life Sciences, Inc. is an Irving, Texas based precision-medicine company that sequences tumors and blood to guide cancer treatment. Its core service is comprehensive molecular profiling: the MI Profile platform runs whole exome and whole transcriptome sequencing on tissue, while the Caris Assure platform does blood-based profiling (an enhanced version was unveiled in September 2026), and newer assays extend into whole genome sequencing, minimal residual disease monitoring (Caris WGS MRD), hematologic profiling (Caris ChromoSeq) and multi-cancer early detection (Caris Detect). Alongside the clinical lab business, Caris licenses access to its multi-modal molecular and clinical database and runs research services for pharmaceutical partners, which is the second revenue line and the reason the company describes itself as an AI or TechBio company rather than a lab.

The investment picture is a business that has crossed from cash-burning to self-funding, and a stock that has swung from pricing in a slowdown to pricing in continued growth. Revenue rose to ~$812 million in 2025 and ~$990 million over the trailing twelve months to June 2026 as clinical volumes grew and, more importantly, average selling price jumped on expanded Medicare and commercial coverage. Q1 2026 revenue of ~$216 million was up ~79% (volume up ~15%, clinical ASP up ~61%), and Q2 2026 revenue of ~$264 million was up ~45%, with molecular profiling revenue up ~55%, clinical case volume up ~18% and gross margin near ~68%. GAAP results sat right at breakeven in both quarters (a net loss of roughly $0.5 million to $0.6 million each), and EPS of $0.00 in Q2 was a cent below the consensus estimate. The shares, which traded near ~$16 in the summer, closed at ~$30.89 on October 16, 2026, up ~96% over three months and ~14.5% year to date though still ~3% lower than a year earlier. The pricing question has not gone away, which is why the debate now centers on how much growth the new valuation needs.

The clearest risk is reimbursement: a large share of recent revenue growth came from price rather than volume, and coverage decisions, rate resets, or payer pushback could reverse that quickly. Growth is already decelerating, from ~79% in Q1 2026 to ~45% in Q2, and analysts expect full-year 2026 revenue of ~$1.03 billion, with quarterly results volatile enough (Q4 2025 revenue of ~$293 million was well above the quarters on either side) that trend-reading is hard. Valuation risk rose sharply with the rally: at ~$8.7 billion the stock trades near ~8.8 times trailing sales and ~83 times 2027 consensus EPS, and insiders have sold shares into the move, including one sale of about $12.1 million disclosed in September 2026. Competition is intense and better capitalized in places, with Foundation Medicine inside Roche, Tempus AI pursuing nearly the same data-plus-sequencing model, and Guardant, Exact Sciences and Grail contesting the blood-based and early-detection frontier. Caris also carries regulatory and legal exposure typical of clinical labs, including a prior ~$2.9 million False Claims Act settlement over billing timing, and lab-developed-test oversight remains an open policy question. Finally, the stock is a recent IPO (June 2025) with a short public track record and a history of large stock-based-compensation charges.

13 analysts publish price targets on CAI, averaging $32.46 against a $32.30 price as of November 2026, or +0.5%. The published targets run from $22.00 to $38.00, a moderate spread, and the ratings split 10 buy, 4 hold, 0 sell. Over the last six months there have been 6 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CAI forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Caris Life Sciences, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Reimbursement-driven pricing (ASP). The single biggest swing factor in recent results has been average selling price, which rose ~61% year over year on clinical therapy-selection tests in Q1 2026 as Medicare and commercial coverage broadened. The most optimistic published target, $38.00, assumes this works close to its best case.

The case against. The clearest risk is reimbursement: a large share of recent revenue growth came from price rather than volume, and coverage decisions, rate resets, or payer pushback could reverse that quickly. The most pessimistic target, $22.00, is roughly what CAI is worth if this bites instead.

Read the full bull and bear case on CAI, including what would have to change to break either one. Walnut is not an investment adviser.

No. Caris Life Sciences, Inc. (CAI) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Caris Life Sciences, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$990M; Q2 2026 revenue ~$264M (+~45% YoY)
• Margins (TTM): ~70% gross, ~10% operating; Q2 2026 gross margin ~68%
• Net income (TTM): ~$105M, boosted by a strong Q4 2025; Q1 and Q2 2026 each near breakeven
• P/E: ~18x trailing, ~83x forward (2027 EPS consensus ~$0.37)
• Cash and debt: ~$793M cash against ~$452M debt
• Market cap: ~$8.7B (~8.8x TTM sales)

Caris's trailing P/E near 18 is flattered by an ~$82 million Q4 2025 profit, since both 2026 quarters were at breakeven, so the market still prices it mainly on sales and on the durability of the pricing gains behind them. That price-to-sales ratio has risen from roughly 5 times in the summer to nearly 9 times after the three-month rally, and BofA lifted its target to $35 from $23 in October. Q3 2026 results are due November 4, 2026, with consensus at ~$0.02 EPS on ~$255 million of revenue.

Other names that sit close to CAI: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CAI exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CAI sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CAI fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Caris is a real, scaling precision-oncology business whose central question is whether the reimbursement-driven pricing gains that doubled revenue can keep compounding once the easy catch-up is behind it; after a ~96% three-month rally, the October 2026 price assumes a good deal of that already.

Whether CAI is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CAI a buy or a sell?, and where the stock could go from here in the CAI stock forecast.

For income investors, whether CAI pays a dividend and how the payout looks is covered in does CAI pay a dividend? And to weigh CAI against a peer, read the full side-by-side comparisons: CAI vs TEM and CAI vs NEO.